ASTS
AST SpaceMobile, Inc.
ASTS offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
CRCT
Cricut, Inc.
CRCT has the edge over ASTS overall, supported by lower modeled downside and stronger valuation.
ASTS Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
ASTS's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
CRCT Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Strong |
CRCT's profitability, cash flow and balance sheet are currently healthy, and its revenue is stable.
ASTS PE Valuation
ASTS has no meaningful PE right now: it lost money over the past year.
CRCT PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $6.15 | -28% |
| Current | 19x | $8.50 | — |
| Fair | 21x | $9.29 | +9.3% |
| Forward | 30x | $8.50 | — |
| Expensive | 34x | $15.24 | +79% |
Historical ranges are pointers, not guarantees.
CRCT's PE is in its fair range at 19x. On analysts' estimates for next year's earnings, today's price would be 30x, in its expensive range.
ASTS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASTS's losses to grow, with revenue growing. However, they disagree widely on these estimates.
CRCT Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for CRCT, with profitability improving.
ASTS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$2.15 | -$0.91 |
| Q2 2026 | -$2.16 | -$0.27 |
| Q1 2026 | -$1.80 | +$0.19 |
| Q4 2025 | -$1.34 | +$0.61 |
| Q3 2025 | -$1.24 | +$0.88 |
| Q2 2025 | -$1.89 | -$0.64 |
| Q1 2025 | -$1.99 | -$1.01 |
| Q4 2022 | -$0.58 | -$0.21 |
ASTS is still losing money, but far less than before: $2.15 per share over the past year, against $5.76 at its worst in mid-2021.
CRCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.28 | -38% |
| Q3 2026 | $0.45 | +18% |
| Q2 2026 | $0.42 | +27% |
| Q1 2026 | $0.34 | +9.7% |
| Q4 2025 | $0.35 | +21% |
| Q3 2025 | $0.38 | +36% |
| Q2 2025 | $0.33 | +6.5% |
| Q1 2025 | $0.31 | +6.9% |
| Q4 2024 | $0.29 | +21% |
CRCT has the edge over ASTS on earnings quality, reporting a profit while its opponent remains loss making.
ASTS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $42.3M | +187% |
| Q2 2026 | $31.5M | +2627% |
| Q1 2026 | $14.7M | +1952% |
| Q4 2025 | $54.3M | +2731% |
| Q3 2025 | $14.7M | +1240% |
| Q2 2025 | $1.2M | +28% |
| Q1 2025 | $718K | +44% |
| Q3 2022 | $4.2M | +70% |
ASTS has the edge over CRCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -415% | +694 points |
| Q2 2026 | -948% | +10744 points |
| Q1 2026 | -1686% | +7083 points |
| Q4 2025 | -175% | +2446 points |
| Q3 2025 | -1109% | +4850 points |
| Q2 2025 | -11692% | -4693 points |
| Q1 2025 | -8769% | +2331 points |
| Q4 2024 | -2621% | N/A |
ASTS's operating margin was −415% last quarter, up 694 points from the same quarter a year ago.
CRCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $188.6M | +11% |
| Q2 2026 | $156.3M | -9.2% |
| Q1 2026 | $159.5M | -1.9% |
| Q4 2025 | $203.6M | -2.7% |
| Q3 2025 | $170.4M | +1.5% |
| Q2 2025 | $172.1M | +2.5% |
| Q1 2025 | $162.6M | -2.8% |
| Q4 2024 | $209.3M | -9.5% |
CRCT's revenue is recovering but still below its 2021 peak: $189M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18% | +4.7 points |
| Q2 2026 | 30% | +13 points |
| Q1 2026 | 14% | -3.7 points |
| Q4 2025 | 6.8% | +0.2 points |
| Q3 2025 | 13% | +7 points |
| Q2 2025 | 17% | +1.7 points |
| Q1 2025 | 18% | +3 points |
| Q4 2024 | 6.6% | -0.5 points |
CRCT has the edge over ASTS on profitability, with a higher operating margin.
ASTS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$464.2M | -$161.4M |
| Q2 2026 | -$694.8M | -$341.1M |
| Q1 2026 | -$309.7M | -$160.7M |
| Q4 2025 | -$330.7M | -$220.3M |
| Q3 2025 | -$302.9M | -$239.1M |
| Q2 2025 | -$353.6M | -$315.3M |
| Q1 2025 | -$149M | -$61.3M |
| Q4 2024 | -$110.5M | -$63.2M |
ASTS has burned cash in almost every quarter: −$1.8B over the past year, against −$916M the year before.
CRCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $23.7M | +16% |
| Q2 2026 | $50.4M | +39% |
| Q1 2026 | $26.9M | -56% |
| Q4 2025 | $82.4M | -20% |
| Q3 2025 | $20.5M | -71% |
| Q2 2025 | $36.2M | +3.4% |
| Q1 2025 | $61.2M | +7.9% |
| Q4 2024 | $103.1M | +12% |
CRCT has the edge over ASTS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASTS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +1.1M shares |
| 1 year | +10% | +27.3M shares |
| 3 years | +235% | +211M shares |
| 5 years | +480% | +248M shares |
| Available history | +944% | +271M shares |
ASTS has 300M diluted shares, up 10% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
CRCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.8% | +1.7M shares |
| 1 year | -1.2% | -2.5M shares |
| 3 years | -3.5% | -7.6M shares |
| 5 years | -5.1% | -11.5M shares |
| Available history | -3.9% | -8.6M shares |
CRCT has the edge over ASTS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5.9M |
| Q2 2026 | $7.5M |
| Q1 2026 | $12.3M |
| Q4 2025 | $5.7M |
| Q3 2025 | $2.4M |
| Q2 2025 | $4.7M |
| Q1 2025 | $12M |
| Q4 2024 | $8M |
CRCT spent $31M buying back its own shares over the past year, up 16% from the year before.
ASTS Net Leverage
ASTS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
CRCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.2x | Net Cash |
| Q2 2026 | -2.0x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -2.1x | Net Cash |
| Q3 2025 | -1.6x | Net Cash |
| Q2 2025 | -2.7x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -2.2x | Net Cash |
CRCT has more cash than debt.
ASTS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.1 | Neutral |
| Stochastic | 11.9 | Oversold |
ASTS's weekly RSI is 34 (neutral) and its Stochastic is 12 (oversold).
CRCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 76.4 | Overbought |
| Stochastic | 74.8 | Neutral |
CRCT's weekly RSI is 76 (overbought) and its Stochastic is 75 (neutral).
ASTS PE vs Technology Sector
ASTS has no meaningful PE right now: it lost money over the past year.
CRCT PE vs Technology Sector
| Metric | CRCT | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 28x | 32% below |
| PE % | 37 | 41 | 4 pts below |
CRCT is trading at 19x earnings, a 32% discount to the Technology sector's median of 28x.
ASTS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $44.9 | 23% below |
| 20 week MA | $57.1 | 40% below |
| 50 week MA | $75.5 | 54% below |
| 100 week MA | $57.8 | 40% below |
| 200 week MA | $33.6 | 2.8% above |
ASTS has fallen below most of its moving averages, though it's still 2.8% above its 200-week average.
CRCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.89 | 23% above |
| 20 week MA | $5.88 | 45% above |
| 50 week MA | $5.01 | 70% above |
| 100 week MA | $5.31 | 60% above |
| 200 week MA | $6.52 | 30% above |
CRCT has the edge over ASTS on trend strength, trading above more of its moving averages.
ASTS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.87 | $13.4 | +36% |
| 2021 | $13.4 | $8.71 | -35% |
| 2022 | $8.71 | $3.97 | -54% |
| 2023 | $3.97 | $6.03 | +52% |
| 2024 | $6.03 | $22.9 | +280% |
| 2025 | $22.9 | $72.0 | +214% |
| 2026 YTD | $72.0 | $34.5 | -52% |
ASTS's yearly returns have swung widely, from +280% in 2024 to −54% in 2022. It's down 52% so far in 2026.
CRCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $18.0 | $23.5 | +30% |
| 2022 | $23.5 | $10.1 | -57% |
| 2023 | $10.1 | $6.59 | -35% |
| 2024 | $6.59 | $5.75 | -13% |
| 2025 | $5.75 | $5.04 | -12% |
| 2026 YTD | $5.04 | $8.50 | +69% |
CRCT has the edge over ASTS on returns for 2026, with the stronger performance.